

Table 18.8
Myeloma

5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year and Age

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
5-Year Relative Survival (Percent)									
Year of Diagnosis:									
1960-1963 ^a	-	-	-	12	13	10	-	-	-
1970-1973 ^a	-	-	-	19	20	17	-	-	-
1975-1977 ^b	24.7	24.1	25.4	24.3	23.7	24.8	29.5	29.3	29.5
1978-1980 ^b	25.9	24.4	27.5	24.8	24.1	25.5	32.5	27.4	37.5
1981-1983 ^b	27.5	25.7	29.3	27.2	25.4	28.9	28.9	29.6	27.9
1984-1986 ^b	27.2	27.6	26.9	25.9	25.7	26.2	31.8	33.3	30.3
1987-1989 ^b	27.2	28.9	25.5	26.9	29.1	24.5	30.0	29.7	30.3
1990-1992 ^b	29.3	30.5	27.9	28.3	29.6	26.9	34.4	38.1	31.0
1993-1995 ^b	31.7	32.1	31.2	30.5	31.2	29.7	35.4	34.9	35.7
1996-1998 ^b	32.4	34.4	30.2	32.1	34.1	29.8	31.4	33.0	30.2
1999-2001 ^b	34.3	36.5	31.7	34.2	36.5	31.3	34.1	36.7	32.0
2002-2004 ^b	42.1	43.0	41.0	42.9	44.2	41.2	40.1	40.2	40.0
2005-2011 ^b	48.5 ^f	49.4 ^f	47.4 ^f	48.1 ^f	49.8 ^f	46.0 ^f	49.5 ^f	47.5 ^f	51.3 ^f
5-Year Period Survival (Percent) ^{cd}									
2011	48.5	49.5	47.2	48.1	49.5	46.3	50.0	49.8	50.2
Stage Distribution (%) 2005-2011 ^{ce}									
All Stages									
Number of cases	29,234	15,887	13,347	21,397	12,005	9,392	5,755	2,773	2,982
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	5	6	4	5	6	4	4	5	4
Regional	0	0	0	0	0	0	0	0	0
Distant	95	94	96	95	94	96	96	95	96
Unstaged	0	0	0	0	0	0	0	0	0
5-Year Relative Survival (Percent), 2005-2011 ^c									
Age at Diagnosis:									
Ages <45	71.1	71.2	71.1	69.8	70.0	69.5	71.5	72.1	70.8
Ages 45-54	63.6	62.3	65.3	65.8	65.2	66.7	56.4	51.5	62.2
Ages 55-64	55.8	55.9	55.5	56.0	56.7	55.1	54.6	53.3	55.9
Ages 65-74	44.9	44.4	45.5	45.5	45.1	46.1	43.4	41.4	45.2
Ages 75+	28.2	29.7	26.9	28.6	30.9	26.4	26.2	27.8	25.5
Ages <65	59.8	59.6	60.2	60.4	60.7	60.0	57.4	54.9	60.2
Ages 65+	36.2	37.4	35.1	36.5	38.1	34.7	35.9	36.2	35.7
Stage ^e :									
All Stages	46.6	47.7	45.2	46.4	48.1	44.2	47.3	46.9	47.7
Localized	68.6	72.4	61.8	69.4	73.8	60.8	61.3	62.3 ^g	59.5 ^g
Regional	-	-	-	-	-	-	-	-	-
Distant	45.4	46.2	44.5	45.1	46.5	43.5	46.7	46.1	47.3
Unstaged	-	-	-	-	-	-	-	-	-

^a Based on End Results data from a series of hospital registries and one population-based registry.

^b SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Based on follow-up of patients into 2012.

^c SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Based on follow-up of patients into 2012.

^d Period survival provides a 2011 estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three year calendar blocks (2009-2011: 0-1 year survival), (2008-2010: 1-2 year survival), (2007-2009: 2-3 year survival), (2006-2008: 3-4 year survival), (2005-2007: 4-5 years survival).

^e Stage at diagnosis is classified using SEER Summary Stage 2000. Stage distribution percentages may not sum to 100 due to rounding.

^f The difference between 1975-1977 and 2005-2011 is statistically significant ($p < .05$).

^g The standard error is between 5 and 10 percentage points.

^h The standard error is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 25 cases during the time period.